Sarepta Therapeutics Financials
| S1RP34 Stock | BRL 21.64 0.56 2.66% |
Sarepta |
Please note, the presentation of Sarepta Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sarepta Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sarepta Therapeutics' management manipulating its earnings.
Sarepta Therapeutics Stock Summary
Sarepta Therapeutics competes with Multilaser Industrial, Vulcan Materials, and Tyson Foods. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. SAREPTA THERDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 866 people.| Instrument | Brazil Stock View All |
| Exchange | Sao Paulo Exchange |
| Business Address | 215 First Street, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.sarepta.com |
| Phone | 617 274 4000 |
| Currency | BRL - Brazilian Real |
You should never invest in Sarepta Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Sarepta Stock, because this is throwing your money away. Analyzing the key information contained in Sarepta Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Sarepta Therapeutics Key Financial Ratios
Sarepta Therapeutics' financial ratios allow both analysts and investors to convert raw data from Sarepta Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Sarepta Therapeutics over time and compare it to other companies across industries.| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 | |||
| Number Of Employees | 840 | |||
| Beta | 0.97 | |||
| Z Score | 31.8 |
Sarepta Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sarepta Therapeutics's current stock value. Our valuation model uses many indicators to compare Sarepta Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sarepta Therapeutics competition to find correlations between indicators driving Sarepta Therapeutics's intrinsic value. More Info.Sarepta Therapeutics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sarepta Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sarepta Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sarepta Therapeutics Systematic Risk
Sarepta Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sarepta Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Sarepta Therapeutics correlated with the market. If Beta is less than 0 Sarepta Therapeutics generally moves in the opposite direction as compared to the market. If Sarepta Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sarepta Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sarepta Therapeutics is generally in the same direction as the market. If Beta > 1 Sarepta Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Sarepta Therapeutics March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sarepta Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sarepta Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sarepta Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Sarepta Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sarepta Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 32.52 | |||
| Value At Risk | (6.21) | |||
| Potential Upside | 3.54 |
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |